Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | EP300 | Q09472 | 11/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7400329 | 0.98 | GBA1 (0.58) | GBA1EP300CREBBPSLC6A4MLNR | |
| SCHEMBL18892649 | 0.84 | EP300 (0.45) | EP300CREBBPSLC6A4 | |
| SCHEMBL894468 | 0.82 | GBA1 (0.59) | GBA1SLC6A4 | |
| SCHEMBL25133411 | 0.82 | GBA1 (0.59) | GBA1SLC6A4 | |
| SCHEMBL9386187 | 0.81 | SIGMAR1 (0.49) | EP300CREBBPSLC6A4 | |
| Hydrochloric Acid SCHEMBL4773715 | 0.81 | GBA1 (0.58) | GBA1SLC6A4 | |
| SCHEMBL9599346 | 0.80 | EED (0.51) | GBA1MLNRADRA2AADRA2BADRA2C | |
| SCHEMBL4245166 | 0.79 | GBA1 (0.66) | GBA1EP300SLC6A4 | |
| SCHEMBL25133603 | 0.79 | GBA1 (0.66) | GBA1EP300SLC6A4 | |
| SCHEMBL9359971 | 0.79 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1DHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20090170901-A1 | Benzoyl Urea Derivatives | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 2009-07-02 | — | — | US | disclosed |
| US-7435744-B2 | Piperidine derivatives as NMDA receptor antagonists | GEDEON RICHTER VEGYESZETI GYAR RT (HU) | 2008-10-14 | — | — | US | disclosed |
| EP-1409477-B1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2008-09-17 | — | — | EP | disclosed |
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | UCB Biopharma SRL (BE) | 2004-08-12 | — | — | US | disclosed |
| EP-1409477-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010159-A1 | PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-02-06 | — | — | WO | disclosed |
| EP-0934932-A1 | QUINOLINE DERIVATIVES AND PSYCHOTROPIC AGENT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157886-A1 | Piperdine derivatives as NMDA receptor antagonists | GRIN1, GRIN2D, GRIN2C | GBA1 4362/4885EP300 1838/4885CREBBP 3896/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | GBA1 2739/4885EP300 677/4885CREBBP 1288/4885 |
| US-20090170901-A1 | Benzoyl Urea Derivatives | OPRM1, GRIN2C, GRIN3A | GBA1 3315/4885EP300 868/4885CREBBP 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.